Share-Based Compensation |
Note 6. Share-Based Compensation In August 2020, the Company adopted the Better Therapeutics Inc. 2020 Stock Option and Grant Plan (the “2020 Plan”) to grant equity-based incentives to officers, directors, consultants and employees. The equity-based incentives include Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards and Unrestricted Stock Awards. A total of 807 thousand shares of the Company’s common stock have been reserved for issuance pursuant to the 2020 plan. Following the closing of the Company’s business combination with Mountain Crest Acquisition Corp. II (the “Business Combination”), no further shares have been issued under the 2020 Plan. In October 2021, the Company adopted the Better Therapeutics Inc. 2021 Stock Option and Incentive Plan (the “2021 Plan”) to grant equity based incentives to officers, directors, consultants and employees. The equity-based incentives include, Incentive Stock Options, Non-Qualified Stock Options, Stock appreciation rights, Restricted Stock Awards, Unrestricted Stock Awards, Cash-based Awards and Dividend Equivalent Rights. A total of 3.6 million shares of common stock were initially reserved for issuance. Additionally, on each January 1 beginning January 1, 2022, the number of shares of common stock reserved and available for issuance under the 2021 Plan will be automatically increased by five percent (5%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as approved by the Administrator of the 2021 Plan. As of June 30, 2023, the Company had a total of 1.5 million shares reserved for issuance under the 2021 Plan. In October 2021, the Company adopted the Better Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”) to provide eligible employees with opportunities to purchase shares of the Company’s common stock. A total of 280 thousand shares of common stock were initially reserved for issuance. Additionally, on each January 1 beginning January 1, 2021, the number of shares of common stock reserved for issuance under the ESPP will be automatically increased by the lesser of (i) 560 thousand shares of common stock, (ii) one percent (1%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the Administrator of the ESPP. As of June 30, 2023, the Company had a total of 501 thousand shares reserved for issuance under the ESPP. In November 2022 , the Company adopted the Better Therapeutics, Inc 2022 Inducement Plan (the “Inducement Plan”) to grant equity awards to prospective officers and employees who are not currently employed by the Company. The equity-based incentives include non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards and dividend equivalent rights. A total of 600 thousand shares of common stock have been initially reserved for issuance under the Inducement Plan. As of June 30, 2023, the Company had a total of 400 thousand shares reserved for issuance under the Inducement Plan. Stock options are exercisable for periods not to exceed 10 years, and vest and contain such other terms and conditions as specified in the applicable award document. Stock options granted with service conditions generally vest over four years with 25% of the option shares vesting one year from the vesting commencement date and then ratably on a monthly basis over the following 36 months. The Company has also issued options with performance-based and market-based vesting conditions. Stock option activity for the periods presented is as follows (in thousands, except share and per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Subject to Options Outstanding |
|
|
Weighted- Average Exercise Price |
|
|
Weighted Average Remaining Contractual Life (Years) |
|
|
Aggregate Intrinsic Value |
|
Balance as of December 31, 2022 |
|
|
3,999,223 |
|
|
$ |
3.95 |
|
|
|
9.3 |
|
|
$ |
64 |
|
Granted |
|
|
984,560 |
|
|
|
1.07 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(1,544 |
) |
|
|
0.50 |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
(366,903 |
) |
|
|
4.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of June 30, 2023 |
|
|
4,615,336 |
|
|
$ |
3.49 |
|
|
|
8.3 |
|
|
$ |
128 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate intrinsic value represents the difference between the exercise price and the fair value of the shares underlying common stock. The weighted-average grant date fair value of stock options granted to employees during the six months ended June 30, 2023, was $0.49 per share. As of June 30, 2023, total unrecognized compensation expense related to unvested stock options was $2.7 million which is expected to be recognized over a weighted-average period of 4.75 years. The fair value of each option award granted is estimated on the grant date. The grant date fair value of options with service and performance-based vesting conditions is determined using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of subjective assumptions, including the fair value of the underlying common stock, the expected term of the option, the expected volatility of the price of the Company’s common stock, risk-free interest rates, and the dividend yield of our common stock. The assumptions used to determine the fair value of the option awards represent the Company’s best estimates. These estimates involve inherent uncertainties and the application of our judgment. The related stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, which is generally four years. The Black-Scholes option pricing model assumptions used in evaluating our awards to employees are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected Term (Years) |
|
|
6.02 |
|
Expected Volatility |
|
|
41 |
% |
Risk-free interest rate |
|
|
4.09 |
% |
Dividend Yield |
|
|
— |
| In July 2022, the Company granted options with performance-based vesting conditions to the Company’s new Chief Executive Officer (“CEO”), which entitled the CEO the right to purchase shares of common stock upon achievement of the Company’s common stock reaching specified market prices for consecutive 90 day periods, the achievement of certain revenue and/or other targets as defined in the award agreements. The performance-based market awards consist of two separate specified award values that vest upon achievement of applicable performance goals, which can result in a vesting range of up to 1.85 million shares in the aggregate. As of June 30, 2023, the performance-based conditions for the awards to the CEO have not been met. The related stock-based compensation expense is being recognized over a remaining period of 7.5 years. During the six months ended June 30, 2023, fifteen thousand shares of common stock vested and converted into unrestricted common stock. As of June 30, 2023 there were 15 thousand shares of restricted stock outstanding. Total stock-based compensation expense for time-based restricted stock of $6 thousand is expected to be recognized on a straight-line basis over approximately the next 6 months for the unvested restricted stock outstanding as of June 30, 2023. In April 2023, the Company issued time-based restricted stock units (“RSUs”) that vest in 2 equal annual installments. RSU activity for the periods presented is as follows:
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2022 |
|
|
— |
|
Granted |
|
|
822,700 |
|
Vested |
|
|
— |
|
Forfeited |
|
|
(28,550 |
) |
|
|
|
|
|
Balance as of June 30, 2023 |
|
|
794,150 |
|
|
|
|
|
| For the six months ended June 30, 2023, the Company recognized $0.1 million in restricted stock compensation expense. Unamortized compensation costs of $0.6 million is being recognized over a weighted average term of 1.73 years. The weighted average grant date fair value of the RSUs granted during the three months ended June 30, 2023 was $0.90 per share. Employee Stock Purchase Plan The ESPP enables eligible employees to purchase the Company’s common stock at a price per share equal to the lesser of 85% of the fair market value of the common stock at the beginning or end of each 24-month offering period. Each offering period will be divided into four purchase periods. The first offering period commenced on February 15, 2022. During the six months ended June 30, 2023, the Company issued 66 thousand shares and recorded $85 thousand of expense in connection with the ESPP. Equity-Based Compensation Expense Equity-based compensation expense in the statement of operations is summarized as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
300 |
|
|
$ |
316 |
|
Sales and marketing |
|
|
48 |
|
|
|
31 |
|
General and administrative |
|
|
540 |
|
|
|
420 |
|
|
|
|
|
|
|
|
|
|
Total equity-based compensation expense |
|
$ |
888 |
|
|
$ |
767 |
|
|
|
|
|
|
|
|
|
| For the six months ended June 30, 2023 and 2022, $28 thousand and $11 thousand of stock based compensation expense was included as part of capitalized internal-use software costs, respectively.
|
12. Share-Based Compensation In August 2020, the Company adopted the Better Therapeutics, Inc. 2020 Stock Option and Grant Plan (the “2020 Plan”) to grant equity-based incentives to officers, directors, consultants and employees. The equity-based incentives include Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, and Restricted Stock Units. A total of 807 thousand shares of the Company’s common stock have been reserved for issuance pursuant to the plan. Upon the close of the Business Combination, no further shares will be issued out of the 2020 Plan. In October 2021, the Company adopted the Better Therapeutics OpCo. Inc., 2021 Stock Option and Incentive Plan (the “2021 Plan”) to grant equity based incentive to officers, directors, consultants and employees. The equity-based incentives include, Incentive Stock Options, Non-Qualified Stock Options, Stock appreciation rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-based Awards and Dividend Equivalent Rights. A total of 3.6 million shares of common stock have been initially reserved for issuance. Additionally, on January 1, 2022 and each January 1 thereafter, the number of shares of common stock reserved and available for issuance under the 2021 Plan shall be cumulatively increased by five percent (5%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as approved by the Administrator of the 2021 Plan (the “Annual Increase”). On January 1, 2023 the Company added 1.2 million shares to the plan for a total reserved for issuance of 3.0 million shares. In October 2021, the Company adopted the ESPP to provide eligible employees with opportunities to purchase shares of the Company’s common stock. A total of 280 thousand shares of common stock were initially reserved for issuance. Additionally, on January 1, 2022 and each January 1 thereafter, the number of shares of common stock reserved for issuance under the ESPP shall be cumulatively increased by the lesser of (i) 560,000 shares of common stock, (ii) one percent (1 %) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the Administrator of the ESPP. On January 1, 2023 the Company added 238,510 shares to the plan for a total reserved for issuance of 566,753 shares. In November 2022, the Company adopted the Better Therapeutics, Inc 2022 Inducement Plan (the “Inducement Plan”) to grant equity awards to prospective officers and employees who are not currently employed by the Company. The equity-based incentives include non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards and dividend equivalent rights. A total of 600,000 shares of common stock have been initially reserved for issuance under the Inducement Plan. Stock options are exercisable for periods not to exceed 10 years, and vest and contain such other terms and conditions as specified in the applicable award document. Stock options granted with service conditions generally vest over four years with 25% of the option shares vesting one year from the vesting commencement date and then ratably on a monthly basis over the following 36 months. The Company has also issued options with performance-based and market-based vesting conditions. Stock option activity for the periods presented is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Subject to Options Outstanding |
|
|
Weighted- Average Exercise Price |
|
|
Weighted Average Remaining Contractual Life (Years) |
|
|
Aggregate Intrinsic Value |
|
Balance as of December 31, 2021 |
|
|
1,476,475 |
|
|
$ |
9.35 |
|
|
|
9.4 |
|
|
$ |
884 |
|
Granted |
|
|
3,595,838 |
|
|
|
1.88 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(60,520 |
) |
|
|
0.50 |
|
|
|
|
|
|
|
|
|
Forfeited |
|
|
(1,012,570 |
) |
|
|
4.66 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2022 |
|
|
3,999,223 |
|
|
$ |
3.95 |
|
|
|
9.3 |
|
|
$ |
64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate intrinsic value represents the difference between the exercise price and the fair value of the shares underlying common stock. The weighted-average grant date fair value of stock options granted to employees during the twelve months ended December 31, 2022 and 2021 was $0.73 and $3.60 per share, respectively. As of December 31, 2022, total unrecognized compensation expense related to unvested stock options was $3.4 million, which is expected to be recognized over a weighted-average period of 2.92 years. The fair value of each option award granted to employees is estimated on the grant date using the Black- Scholes option pricing model. The Black-Scholes option pricing model requires the input of subjective assumptions, including the fair value of the underlying common stock, the expected term of the option, the expected volatility of the price of our common stock, risk-free interest rates, and the dividend yield of the Company’s common stock. The assumptions used to determine the fair value of the option awards represent our best estimates. These estimates involve inherent uncertainties and the application of the Company’s judgment. The related stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, which is generally four years.
The Black-Scholes option pricing model assumptions used in evaluating our awards to employees are as follows:
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2022 |
|
|
Year Ended December 31, 2021 |
|
Expected Term (Years) |
|
|
6.09 |
|
|
|
6.02 |
|
Expected Volatility |
|
|
41.0 |
% |
|
|
42.0 |
% |
Risk-free interest rate |
|
|
2.74 |
% |
|
|
1.22 |
% |
Dividend Yield |
|
|
— |
|
|
|
— |
| In July 2022, the Company granted options with performance-based vesting conditions to the Company’s new Chief Executive Officer (“CEO”), which entitle the CEO with the right to purchase shares of common stock upon achievement of the Company’s common stock reaching specified market prices for consecutive 90 day periods, the achievement of certain revenue and/or other targets as defined in the award agreements. The performance-based market awards consist of two separate specified award values that vest upon achievement of applicable performance goals, which can result in a vesting range of up to 1,850,000 shares in the aggregate. As of December 31, 2022, the performance-based conditions for the awards to the CEO have not been met. The related stock-based compensation expense is being recognized over a period of 8.0 years. The total grant date fair value of performance-based market condition share awards granted during the twelve months ended December 31, 2022 was $31 thousand. The estimated fair values of these awards was determined using a Monte-Carlo valuation simulation, with the following most significant assumptions:
|
|
|
|
|
|
|
Year Ended December 31, 2022 |
|
Valuation date stock price |
|
|
1.68 |
|
Valuation date to end of performance period (Years) |
|
|
10.00 |
|
Expected Volatility |
|
|
38.8 |
% |
Risk-free interest rate |
|
|
2.80 |
% |
Dividend Yield |
|
|
— |
| During the twelve months ended December 31, 2022, 172 thousand shares of common stock vested and converted into unrestricted common stock. During the twelve months ended December 31, 2021 52,263 shares were forfeited and 235,634 shares vested and were converted into unrestricted common stock. As of December 31, 2022 there were 30 thousand shares of restricted stock outstanding. Total stock-based compensation expense for time-based restricted stock of $13 thousand is expected to be recognized on a straight-line basis over approximately the next 0.5 years for the unvested restricted stock outstanding as of December 31, 2022. Employee Stock Purchase Plan The ESPP enables eligible employees to purchase the Company’s common stock at a price per share equal to the lesser of 85% of the fair market value of the common stock at the beginning or end of each 24 month offering period. Each offering period will be divided into four purchase periods. The first offering period commenced on February 15, 2022. During the twelve months ended December 31, 2022 the Company issued 187,784 shares and recorded $134 thousand of expense in connection with the ESPP. Equity-Based Compensation Expense Equity-based compensation expense in the statement of operations is summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
555 |
|
|
$ |
250 |
|
Sales and marketing |
|
|
(7 |
) |
|
|
6 |
|
General and administrative |
|
|
1,276 |
|
|
|
390 |
|
|
|
|
|
|
|
|
|
|
Total equity-based compensation expense |
|
$ |
1,824 |
|
|
$ |
646 |
|
|
|
|
|
|
|
|
|
| For the twelve months ended December 31, 2022 and 2021, $33 thousand and $40 thousand of stock based compensation expense was included as part of capitalized internal-use software costs, respectively.
|